Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 10, 2023 22:15 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank

BOSTON, March 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
March 06, 2023 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
March 01, 2023 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
February 28, 2023 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development

BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
February 02, 2023 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
January 25, 2023 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates

BOSTON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
November 10, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights

– Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency for the Safety of Medicines (ANSM) in France – – TNG260 disclosed as a...
November 07, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
October 19, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

BOSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines,...
October 05, 2022 08:10 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting

CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...